The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the authors’ institutions.

Dr. Gibson reports receiving consulting fees from Teva Pharmaceuticals. Dr. Claassen reports receiving research support from the Griffin Family Foundation and the Huntington Disease Society of America; pharmaceutical grant support from AbbVie, Acadia, Alterity, Biogen, BMS, Cerecour, Eli Lilly, Genentech-Roche, Jazz Pharmaceuticals, Lundbeck, Neurocrine, Teva Neuroscience, UniQure, Vaccinex, and Wave Life Sciences; and consulting fees from Acadia, Adamas, Alterity, Anexon, Ceruvel, Lundbeck, Neurocrine, Spark, Teva Neuroscience, and UniQure. Dr. Brown reports receiving research support from CHDI Foundation and Parkinson’s Foundation; pharmaceutical grant support from AbbVie, Alterity Therapeutics, Amylyx Pharmaceuticals, Genentech-Roche, Neurocrine Biosciences, Novartis, Orphalan, PTC Therapeutics, Sage Therapeutics, Teva Neuroscience, and UniQure; and consulting fees from Orphalan. Dr. Isaacs reports receiving research funding from Teva Neuroscience and the Tourette Association of America. The other authors report no financial relationships with commercial interests.